BANB Stock Overview
Bachem Holding AG provides products for research, clinical development, and commercial application to pharmaceutical and biotechnology companies worldwide.
Bachem Holding Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||CHF70.10|
|52 Week High||CHF171.00|
|52 Week Low||CHF67.00|
|1 Month Change||-21.17%|
|3 Month Change||-34.61%|
|1 Year Change||-27.66%|
|3 Year Change||179.51%|
|5 Year Change||192.33%|
|Change since IPO||400.71%|
Recent News & Updates
I Ran A Stock Scan For Earnings Growth And Bachem Holding (VTX:BANB) Passed With Ease
For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...
What You Can Learn From Bachem Holding AG's (VTX:BANB) P/E After Its 29% Share Price Crash
Bachem Holding AG ( VTX:BANB ) shareholders that were waiting for something to happen have been dealt a blow with a 29...
|BANB||CH Life Sciences||CH Market|
Return vs Industry: BANB underperformed the Swiss Life Sciences industry which returned -10.8% over the past year.
Return vs Market: BANB underperformed the Swiss Market which returned -2.5% over the past year.
|BANB Average Weekly Movement||7.0%|
|Life Sciences Industry Average Movement||7.1%|
|Market Average Movement||4.9%|
|10% most volatile stocks in CH Market||8.6%|
|10% least volatile stocks in CH Market||2.5%|
Stable Share Price: BANB is more volatile than 75% of Swiss stocks over the past 3 months, typically moving +/- 7% a week.
Volatility Over Time: BANB's weekly volatility (7%) has been stable over the past year, but is still higher than 75% of Swiss stocks.
About the Company
Bachem Holding AG provides products for research, clinical development, and commercial application to pharmaceutical and biotechnology companies worldwide. The company engages in the development, production, and regulatory support of peptide active pharmaceutical ingredients, such as peptide and oligonucleotide new chemical entities (NCEs). It also offers commercial NCEs and generics; and project management, quality and regulatory, analytical, good manufacturing practice production, research grade production, and supply and vertical integration services.
Bachem Holding Fundamentals Summary
|BANB fundamental statistics|
Is BANB overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|BANB income statement (TTM)|
|Cost of Revenue||CHF336.51m|
Last Reported Earnings
Dec 31, 2021
Next Earnings Date
Aug 25, 2022
|Earnings per share (EPS)||1.56|
|Net Profit Margin||22.79%|
How did BANB perform over the long term?See historical performance and comparison
1.0%Current Dividend Yield
Is Bachem Holding undervalued compared to its fair value and its price relative to the market?
Valuation Score 1/6
Below Fair Value
Significantly Below Fair Value
PE vs Industry
PE vs Market
PB vs Industry
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: BANB (CHF70.1) is trading below our estimate of fair value (CHF80.43)
Significantly Below Fair Value: BANB is trading below fair value, but not by a significant amount.
Price To Earnings Ratio
PE vs Industry: BANB's Price-To-Earnings Ratio (45.1x) is in line with the Swiss Life Sciences industry average.
PE vs Market: BANB is poor value based on its Price-To-Earnings Ratio (45.1x) compared to the Swiss market (17.9x).
Price to Earnings Growth Ratio
PEG Ratio: BANB is poor value based on its PEG Ratio (2.7x)
Price to Book Ratio
PB vs Industry: BANB is overvalued based on its Price-To-Book Ratio (4.6x) compared to the CH Life Sciences industry average (4.2x).
How is Bachem Holding forecast to perform in the next 1 to 3 years based on estimates from 5 analysts?
Future Growth Score3/6
Future Growth Score 3/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: BANB's forecast earnings growth (16.5% per year) is above the savings rate (-0.3%).
Earnings vs Market: BANB's earnings (16.5% per year) are forecast to grow faster than the Swiss market (5.9% per year).
High Growth Earnings: BANB's earnings are forecast to grow, but not significantly.
Revenue vs Market: BANB's revenue (15.1% per year) is forecast to grow faster than the Swiss market (4.3% per year).
High Growth Revenue: BANB's revenue (15.1% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: BANB's Return on Equity is forecast to be low in 3 years time (14.3%).
How has Bachem Holding performed over the past 5 years?
Past Performance Score3/6
Past Performance Score 3/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: BANB has a high level of non-cash earnings.
Growing Profit Margin: BANB's current net profit margins (22.8%) are higher than last year (19.4%).
Past Earnings Growth Analysis
Earnings Trend: BANB's earnings have grown significantly by 22.8% per year over the past 5 years.
Accelerating Growth: BANB's earnings growth over the past year (46.9%) exceeds its 5-year average (22.8% per year).
Earnings vs Industry: BANB earnings growth over the past year (46.9%) underperformed the Life Sciences industry 50.8%.
Return on Equity
High ROE: BANB's Return on Equity (10.2%) is considered low.
How is Bachem Holding's financial position?
Financial Health Score6/6
Financial Health Score 6/6
Short Term Liabilities
Long Term Liabilities
Financial Position Analysis
Short Term Liabilities: BANB's short term assets (CHF833.7M) exceed its short term liabilities (CHF134.6M).
Long Term Liabilities: BANB's short term assets (CHF833.7M) exceed its long term liabilities (CHF42.9M).
Debt to Equity History and Analysis
Debt Level: BANB has more cash than its total debt.
Reducing Debt: BANB's debt to equity ratio has reduced from 15.2% to 1.8% over the past 5 years.
Debt Coverage: BANB's debt is well covered by operating cash flow (487.8%).
Interest Coverage: BANB's interest payments on its debt are well covered by EBIT (359.1x coverage).
What is Bachem Holding current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Future Dividend Coverage
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: BANB's dividend (1%) isn’t notable compared to the bottom 25% of dividend payers in the Swiss market (1.92%).
High Dividend: BANB's dividend (1%) is low compared to the top 25% of dividend payers in the Swiss market (3.91%).
Stability and Growth of Payments
Stable Dividend: BANB is not paying a notable dividend for the Swiss market, therefore no need to check if payments are stable.
Growing Dividend: BANB is not paying a notable dividend for the Swiss market, therefore no need to check if payments are increasing.
Earnings Payout to Shareholders
Earnings Coverage: BANB is not paying a notable dividend for the Swiss market.
Cash Payout to Shareholders
Cash Flow Coverage: BANB is paying a dividend but the company has no free cash flows.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Thomas Meier (53 yo)
Mr. Thomas Meier has been Chief Executive Officer of Bachem Holding AG since 2020. Mr. Meier served as Chief Operations Officer at Bachem Group since January 1, 2019 until 2020. He joined Bachem AG in 1993...
CEO Compensation Analysis
Compensation vs Market: Thomas's total compensation ($USD652.47K) is below average for companies of similar size in the Swiss market ($USD2.26M).
Compensation vs Earnings: Thomas's compensation has been consistent with company performance over the past year.
Experienced Management: BANB's management team is not considered experienced ( 0.3 years average tenure), which suggests a new team.
Experienced Board: BANB's board of directors are considered experienced (9.2 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 5.4%.
Bachem Holding AG's employee growth, exchange listings and data sources
- Name: Bachem Holding AG
- Ticker: BANB
- Exchange: SWX
- Founded: 1971
- Industry: Life Sciences Tools and Services
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: CHF5.170b
- Shares outstanding: 73.75m
- Website: https://www.bachem.com
Number of Employees
- Bachem Holding AG
- Hauptstrasse 144
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/05/26 00:00|
|End of Day Share Price||2022/05/25 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.